SCHEMBL5754107

SCHEMBL5754107

Cc1ccc(C2=NC(C)(C)CN2C(c2cc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KIF11 P52732 3/20 0.39
MAP1LC3B Q9GZQ8 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
KCNH2 Q12809 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
MAPK8 P45983 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
P2RX7 Q99572 1/20 0.35
MAPK9 P45984 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864327 0.93 CYP2C19 (0.40) ALDH1A1MEN1KMT2AKIF11MAP1LC3B
SCHEMBL5786959 0.92 L3MBTL1 (0.37) ALDH1A1KIF11MAP1LC3BCYP3A4CYP2C19
SCHEMBL5863996 0.91 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL5863779 0.91 TDP1 (0.36) KIF11MAP1LC3BCYP3A4CYP2C19KCNH2
SCHEMBL5752888 0.90 KIF11 (0.41) KIF11MAP1LC3BCYP3A4CYP2C19KCNH2
SCHEMBL5864191 0.88 PDE4A (0.39) ALDH1A1TDP1PTGS1PTGS2KDM4E
SCHEMBL5863739 0.88 MAPK8 (0.38) ALDH1A1MEN1KMT2AKIF11CYP3A4
SCHEMBL4514039 0.87 KIF11 (0.50) ALDH1A1MEN1KMT2AKIF11MAP1LC3B
SCHEMBL5754034 0.86 GRIN1 (0.39) CYP3A4CYP2C19TDP1PTGS1PTGS2
SCHEMBL5864291 0.85 TDP1 (0.42) ALDH1A1KMT2AKIF11MAP1LC3BCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556357-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2006-09-13 EP disclosed
US-7041676-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2006-05-09 US disclosed
US-20060019988-A1 Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity CYTOKINETICS, INC. 2006-01-26 US disclosed
EP-1556357-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-07-27 EP disclosed
US-20040082567-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2004-04-29 US disclosed
WO-2003106426-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019988-A1 Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity KIF5B, KIF2C, KIF18A ALDH1A1 1833/4885MEN1 2174/4885KMT2A 1363/4885
US-20040082567-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 ALDH1A1 2274/4885MEN1 1507/4885KMT2A 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.